(Q43782014)

English

Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice.

scientific article published on 21 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

experimental autoimmune encephalomyelitis

1 reference

based on heuristic

inferred from title

cinnavalininate

1 reference

based on heuristic

inferred from title

object named as

Cinnabarinic acid

31 May 2024

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francesca Fallarino

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francesco Fazio

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Serena Notartomaso

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Carla L Busceti

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Pamela Scarselli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Massimo Allegrucci

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maria Laura Belladonna

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ferdinando Nicoletti

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Cristina Zappulla

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alban Bessede

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Luana Lionetto

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maurizio Simmaco

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

21 February 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Neuropharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

81

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

237-243

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors

2 references

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1124/MOL.111.074765

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Cinnabarinic acid generated from 3-hydroxyanthranilic acid strongly induces apoptosis in thymocytes through the generation of reactive oxygen species and the induction of caspase

2 references

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1002/JCB.21384

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Kynurenines in Parkinson's disease: therapeutic perspectives.

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Mice resistant to experimental autoimmune encephalomyelitis have increased thymic expression of myelin basic protein and increased MBP specific T cell tolerance

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Isolation of brain-infiltrating leukocytes

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor

2 references

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1038/NATURE06880

Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

2 references

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

31 May 2024

https://opencitations.net/index/api/v1/citations/10.4049/JIMMUNOL.0903670

Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

The relevance of animal models in multiple sclerosis research

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

2 references

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1084/JEM.20020052

The role of antigen presenting cells in multiple sclerosis

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Recent neuropathological findings in MS--implications for diagnosis and therapy

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation.

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

CTLA-4-Ig regulates tryptophan catabolism in vivo.

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autoptic cerebellar samples from patients with multiple sclerosis.

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

1 reference

31 May 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.02.011

Identifiers

10.1016/J.NEUROPHARM.2014.02.011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24565643%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43782014&oldid=2169683887"